IP Library Granted Patent US 7,319,141
Granted Patent B2
US 7,319,141 · App. 10/968,674 · Granted Jan 15, 2008

Stem cell growth factor-like polypeptides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,319,141
App. No.
10/968,674
Granted
Jan 15, 2008
Kind
B2
Abstract

The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human stem cell growth factor-like protein. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries from human testis cells (Hyseq clone identification numbers 2880984 and 2881695), from human fetal skin (Hyseq clone identification number 15375176), adult spleen (Hyseq clone identification number 14856094), and human endothelial cells (Hyseq clone identification numbers 13804756, 13687487, 13804756). Other aspects of the invention include vectors containing processes for producing novel human stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.

Claims (17)

1. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 13, 16, 32 or 34, or the mature protein portion thereof, or a polypeptide with at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 13, 16, 32 or 34 or the mature protein portion thereof that retains stem cell growth factor activity.

2. The polypeptide of claim 1 with the proviso that said polypeptide does not consist of the amino acid sequence of SEQ ID NO: 48.

3. The polypeptide of claim 1 , wherein the polypeptide comprises one or more motifs selected from the group of a laminin-type EGF-like domain, a membrane attack complex component/perforin domain, and neurohypophysial hormone signature.

4. The polypeptide according to claim 1 , which is modified with one or more modifying agents selected from the group consisting of polyethylene glycol (PEG), dextran, poly(N-vinyl-pyrrolidone), polypropylene glycol homopolymer, copolymer of polypropylene oxide/ethylene oxide, polyoxyethylated polyol and polyvinyl alcohol.

5. A kit comprising the polypeptide of claim 1 .

6. A composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier or diluent.

7. An isolated polypeptide consisting of the mature protein portion of SEQ ID NO: 13, 16, 32 or 34.

8. A composition comprising the polypeptide of claim 7 and a pharmaceutically acceptable carrier or diluent.

9. An isolated polypeptide consisting of the amino acid sequence of amino acid residues 22 to 279 of SEQ ID NO: 32, or an amino acid sequence with at least 98% sequence identity thereto that retains stem cell growth factor activity.

10. A composition comprising the polypeptide of claim 9 and a pharmaceutically acceptable carrier or diluent.

11. An isolated polypeptide consisting of the amino acid sequence of amino acid residues 22 to 272 of SEQ ID NO: 34, or an amino acid sequence with at least 98% sequence identity thereto that retains stem cell growth factor activity.

12. A composition comprising the polypeptide of claim 11 and a pharmaceutically acceptable carrier or diluent.

13. An isolated polyp eptide with stem cell growth factor activity, said polypeptide comprising at least 272 amino acids and having at least 98% identity with SEQ ID NO: 10.

14. An isolated polypeptide with stem cell growth factor activity having at least 98% sequence identity with SEQ ID NO: 10, 13, or 16 and lacking amino acid sequence GIEVTLAEGLTSVSQRTQPTPCRRRYL (SEQ ID NO: 29) wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E=Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine.

15. An isolated polypeptide with stem cell growth factor activity having at least 98% sequence identity with SEQ ID NO: 10, 13, or 16 and lacking any 10 consecutive amino acids from an amino acid sequence GIEVTLAEGLTSVSQRTQPTPCRRRYL (SEQ ID NO: 29), wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E=Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine.

16. An isolated mature polypeptide expressed by a polynucleotide comprising the protein coding cDNA insert of the plasmid deposited with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology Zip code 305-8566; Higashi 1-1-3, Tsukuba, Ibaraki, Japan) on Jun. 26, 2000 under accession number FERM BP-7198, in a suitable host cell.

17. An isolated mature polypeptide expression product expressed by a polynucleotide comprising the protein coding cDNA insert of the plasmid deposited with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (Zip code 305-8566; Higashi 1-1-3, Tsukuba, Ibaraki, Japan) on Jun. 26, 2000 under accession number FERM BP-7197, in a suitable host cell.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE AND ASSIGNOR'S NAME PREVIOUSLY RECORDED ON REEL 022390 FRAME 0234. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded May 26, 2021
From: KYOWA HAKKO KOGYO CO., LTD.
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 056583/0647 →
MERGER Recorded Mar 13, 2009
From: KIRIN PHARMA CO., LTD.
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 022390/0234 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2008
From: NUVELO, INC.
To: KIRIN PHARMA KABUSHIKI KIAHSA
Reel/Frame 021339/0545 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2008
From: KIRIN HOLDINGS KABUSHIKI KAISHA
To: KIRIN PHARMA KABUSHIKI KAISHA
Reel/Frame 021339/0550 →
CHANGE OF NAME Recorded Jul 11, 2008
From: KIRIN BEER KABUSHIKI KAISHA
To: KIRIN HOLDINGS KABUSHIKI KAISHA
Reel/Frame 021217/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2006
From: CHAO, CHENG-CHI
To: NUVELO, INC.
Reel/Frame 017198/0681 →